ROCHE HLDG - Dusseldorf Stock Exchang (RHO DU) stock market data APIs
€295.1362
7.56(2.6%)
as of September 15, 2025
Try our APIs with
free plan!
ROCHE HLDG - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for RHO.DU.
Prev. Close
295.1362
Open
302.6976
High
302.6976
Low
295.1362
52 wk Range
235.2567-313.4
Market Cap
312 681 M
Dividends (Yield)
0.0415
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ROCHE HLDG - Dusseldorf Stock Exchang data using free add-ons & libraries
Get ROCHE HLDG - Dusseldorf Stock Exchang Fundamental Data
ROCHE HLDG - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get ROCHE HLDG - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ROCHE HLDG - Dusseldorf Stock Exchang News
New
Top Analyst Reports for Roche, Linde & Walt Disney
Monday, September 15, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Roche H...
PBYI Surges 30% in 3 Months: How Should You Play the Stock?
Puma Biotechnology PBYI stock delivered a solid performance in the past three months, with its shares rallying 29.6% compared with the industry’s rise of 3.9%. The stock has also outperformed the se...
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
Shares of Regeneron Pharmaceuticals (REGN) have lost 21.1% year to date against the industry’s growth of 5.2%. The stock has also underperformed the sector and the S&P 500 Index during this time fra...
Novartis Catches a ‘Sell.’ Goldman Sachs Says the Stock Is Overvalued.
Stock in one of the world’s largest pharmaceutical companies, Novartis fell after Goldman Sachs said its valuation looks stretched and reminded investors that patents are expiring on some of the com...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
